This research will be conducted by the SIU Memory and Aging Network (MAN), which comprises 38 sites that evaluate and treat patients with dementia throughout non-metropolitan Illinois. AD patients and their caregivers who are living in private homes will be recruited. Primary outcome measures will be the ratings of the caregiver’s physical status (grip strength, walking speed, and score on the Timed Up-and-Go Test11 and the rating of the caregiver’s chronic medical illness burden using the Cumulative Illness Rating Scale (Geriatric).12,13 The patient and caregiver dyad is required.
The purpose of the study is to demonstrate the safety and effectiveness of the BioVentrix Revivent TC System for the treatment of LV antero-septal aneurysms/scars in patients with symptomatic heart failure.
MOVR: Data Hub is the first and only data hub that aggregates clinical, genetic, and patient reported data for multiple nuromuscular diseases. Collection of patient data about disease progression in the era of new treatments will inform and accelerate future innovation. The combination of data collected through MOVR Data Hub will provide a comprehensive understanding of health and patient experiences in a single data repository. MOVR Data Hub has the power to transform health outcomes, accelerate drug development and drive clinical research across multiple neuromuscular diseases, helpin
NXDC-MEN-301: Subjects are being asked to participate in this study because they have a brain tumor, a meningioma, and surgery is recommended to remove it. The sponsor of this clinical trial, NX Development Corp, has developed the study drug, Gleolan, an imaging agent that in some brain tumors, can make the tumors glow red-violet under a special blue light. This may make it easier for the study surgeon to identify the tumor and to remove it. As part of the study, subjects will drink the Gleolan before your surgery. The goal is to safely remove the tumor.
PADOVA: The purpose of this study is to find out what effects, good and/or bad, prasinezumab versus placebo has on Parkinson’s disease in people who are taking standard medication to manage the disease symptoms.